Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease

Journal of the Neurological Sciences

Volumn 223, Issue 2, 2004, Pages 161-166

  Sohmiya, Makoto ^a   Tanaka, Makoto ^a   Wei Tak, Nyou ^b   Yanagisawa, Makoto ^b   Tanino, Yutaka ^c   Suzuki, Yoko ^a   Okamoto, Koichi ^a   Yamamoto, Yorihiro ^c  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO UNIVERSITY OF TECHNOLOGY   (Japan)

Author keywords

Antioxidant; Coenzyme Q10; Oxidative stress; Parkinson's disease; Plasma; Redox status

Indexed keywords

UBIDECARENONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROCHEMISTRY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; PLASMA; STATISTICS, NONPARAMETRIC; UBIQUINONE;

EID: 4444278377     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2004.05.007     Document Type: Article

References (48)

1. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170
2. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836
3. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B.H. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:1991;978-982
4. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex deficiency in Parkinson's disease. Lancet. 1:1989;1269
5. Marttila R.J., Lorentz H., Rinne U.K. Oxygen toxicity protecting enzymes in Parkinson's disease. J. Neurol. Sci. 86:1988;321-331
6. Saggu H., Cooksey J., Dexter D., Wells F.R., Lees P., Marsden C.D. A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem. 53:1989;692-697
7. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310
8. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389
9. Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells F.R., Daniel S.E., et al. Increased levels of lipid hydroperoxides in the Parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9:1994;92-97
10. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 93:1996;2696-2701
11. Sanchez-Ramos J., Overvik E., Ames B.N. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′ deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration. 3:1994;197-204
12. Parker W., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723
13. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:1992;782-788
14. Benecke R., Strumper P., Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 116:1993;1451-1463
15. Bindoff L.A., Birch-Machin M., Cartlidge N.E., Parker W., Turnbull D.M. Mitochondrial function in Parkinson's disease. Lancet. 2:1989;49
16. Shoffner J.M., Watts R.L., Juncos J.L., Torroni A., Wallace D.C. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30:1991;332-339
17. Bindoff L.A., Birch-Machin M.A., Cartlidge N.E., Parker W.D. Jr., Turnbull D.M. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J. Neurol. Sci. 104:1991;203-208
18. Nakagawa-Hattori Y., Yoshino H., Kondo T., Mizuno Y., Horai S. Is Parkinson's disease a mitochondrial disorder? J. Neurol. Sci. 107:1992;29-33
19. Cardellach F., Marti M.J., Fernandez-Sola J., Marin C., Hoek J.B., Tolosa E., et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology. 43:1993;2258-2262
20. Blin O., Desnuelle C., Rascol O., Borg M., Peyro Saint Paul H., Azulay J.P., et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci. 125:1994;95-101
21. Barroso N., Campos Y., Huertas R., Esteban J., Molina J.A., Alonso A., et al. Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson disease. Clin. Chem. 39:1993;667-669
22. Bravi D., Anderson J.J., Dagani F., Davis T.L., Ferrari R., Gillespie M., et al. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Mov. Disord. 7:1992;228-231
23. DiDonato S., Zeviani M., Giovannini P., Savarese N., Rimoldi M., Mariotti C., et al. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology. 43:1993;2262-2268
24. Martin M.A., Molina J.A., Jimenez-Jimenez F.J., Benito-Leon J., Orti-Pareja M., Campos Y., et al. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Neurology. 46:1996;1343-1346
25. Molina J.A., Ruiz-Pesini E., Jimenez-Jimenez F.J., Lopez-Perez M.J., Alvarez E., Berbel A., et al. Respiratory chain enzyme activities in spermatozoa from untreated Parkinson's disease patients. J. Neural Transm. 106:1999;919-924
26. Ahlskog J.E., Uitti R.J., Low P.A., Tyce G.M., Nickander K.K., Petersen R.C., et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov. Disord. 10:1995;566-573
27. Fernandez-Calle P., Molina J.A., Jimenez-Jimenez F.J., Vazquez A., Pondal M., Garcia-Ruiz P.J., et al. Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease. Neurology. 42:1992;1064-1066
28. Foy C.J., Passmore A.P., Vahidassr M.D., Young I.S., Lawson J.T. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. Q. J. Med. 92:1999;39-45
29. Jimenez-Jimenez F.J., Molina J.A., de Bustos F., Garcia-Redondo A., Gomez-Escalonilla C., Martinez-Salio A., et al. Serum levels of coenzyme Q10 in patients with Parkinson's disease. J. Neural Transm. 107:2000;177-181
30. Jimenez-Jimenez F.J., Molina J.A., Fernandez-Calle P., Vazquez A., Cabrera-Valdivia F., Catalan M.J., et al. Serum levels of beta-carotene and other carotenoids in Parkinson's disease. Neurosci. Lett. 157:1993;103-106
31. Yamamoto Y., Kawamura M., Tatsuno K., Yamashita S., Niki E., Naito C. Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein. Davies K.J.A. Oxidative damage and repair. 1991;287-291 Pergamon, London
32. Yamashita S., Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal. Biochem. 250:1997;66-73
33. Yamamoto Y., Yamashita S., Fujisawa A., Kokura S., Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis and hepatoma evaluated by plasma antioxidants. Biochem. Biophys. Res. Commun. 247:1998;166-170
34. Hara K., Yamashita S., Fujisawa A., Ishiwa S., Ogawa T., Yamamoto Y. Oxidative stress in newborn infants with and without asphyxia as measured by plasma antioxidants and free fatty acid. Biochem. Biophys. Res. Commun. 257:1999;244-248
35. Yamamoto Y., Yamashita S. Plasma ubiquinone and ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion. BioFactors. 9:1999;241-246
36. Calne D.B., Snow B.J., Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32:1992;S125-S127
37. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944
38. Hoehn M.H., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology. 17:1967;427-442
39. Fahn S., Elton R. Members of the UPDRS development committee. Unified Parkinson's Disease rating scale. Fahn S., Marsden C.D., Calne D.B., Goldsetin M. Recent developments in Parkinson's disease. vol. 2:1987;153-164 Macmillan Healthcare Information, Florham Park (NJ)
40. Yamamoto Y., Ames B.N. Detection of lipid hydroperoxides and hydrogen peroxide at picomole levels by an HPLC and isoluminol chemiluminescence assay. Free Radic. Biol. Med. 3:1987;359-361
41. Molina J.A., de Bustos F., Jimenez-Jimenez F.J., Benito-Leon J., Orti-Pareja M., Gasalla T., et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. J. Neural Transm. 104:1997;1287-1293
42. Konings C.H., Kuiper M.A., Teerlink T., Mulder C., Scheltens P., Wolters E.C. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol. Sci. 168:1999;112-115
43. Abe T., Isobe C., Murata T., Sato C., Tohgi H. Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci. Lett. 336:2003;105-108
44. Kikuchi A., Takeda A., Onodera H., Kimpara T., Hisanaga K., Sato N., et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9:2002;244-248
45. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59:2002;1541-1550
46. Shults C.W., Haas R.H., Passov D., Beal M.F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42:1997;261-264
47. Shults C.W., Beal M.F., Fontaine D., Nakano K., Haas R.H. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 50:1998;793-795
48. Matthews R.T., Yang L., Browne S., Baik M., Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8892-8897